Beyond Air, Inc. (XAIR)

In January 2026, XAIR shares rallied after XTL Biopharmaceuticals Ltd. announced a deal to acquire a majority stake in Beyond Air's subsidiary NeuroNOS Ltd. In November 2025, the company reported its Q2 FY2026 financial results, missing EPS and revenue forecasts, but operating expenses and net cash burn decreased. Also in November 2025, Beyond Air's stock surged after securing financing agreements with Streeterville Capital. In September 2025, NeuroNOS received FDA Orphan Drug Designation for its treatment targeting malignant glioma, and the company reaffirmed its fiscal year 2026 revenue forecast. In August 2025, Beyond Air announced new international distribution agreements for LungFit PH, expanding into Japan. Also in August 2025, the company reported its Q1 FY2026 financial results, showing a modest earnings beat but a revenue miss, and indicated a potential need for additional funding. In July 2025, a reverse stock split was effected. In February 2025, Beyond Air was granted an extension by Nasdaq to regain compliance with the minimum bid price rule.

Information explicitly detailing demand seasonality for Beyond Air, Inc.'s products and services was not found in the provided search results. While the company's focus on respiratory illnesses could suggest potential seasonal variations in demand, this is an inference and not directly stated by the company or in market analyses.

Beyond Air, Inc. (XAIR) is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide (NO) to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors. The company operates in the Health Technology sector, specifically in the Medical Specialties and Medical Device industries. Beyond Air's core technology is the LungFit™ system, which generates nitric oxide from ambient air for precise delivery to the lungs. Key products include LungFit PH (approved for PPHN and under investigation for other conditions), LungFit PRO (an investigational device for viral lung infections), LungFit GO (an investigational device for at-home treatment of NTM lung infection), the Air Disinfection System (ADS), and a Medical Nitrous Oxide (N₂O) Delivery System. The company also has segments focused on cancer and neurological disorders.

Beyond Air, Inc. is headquartered in Garden City, New York, USA. The company has been expanding its international presence, with its LungFit PH distribution network reaching 35 countries as of late 2025 and plans to reach 60 by 2026. Recent distribution agreements include countries such as France, Turkey, Romania, Morocco, Japan, and South Korea.

Beyond Air's brand reputation has been characterized by efforts to expand its global market presence and highlight product innovation. The company is positioning itself as a key player in the respiratory medical device market, aiming to offer transformative treatment options. Its international expansion and partnerships are seen as drivers for greater market access and sustained revenue growth in advanced respiratory care. Product innovation and operational efficiencies are also noted as factors improving scalability and margin potential.

Beyond Air, Inc. has a mix of institutional and individual ownership. Insiders own approximately 17.00% of the company's stock, with Robert Carey being the largest individual insider shareholder. Institutional shareholders hold around 21.49% of Beyond Air's stock, with Alyeska Investment Group LP and Balyasny Asset Management LP being key institutional owners.